6-Methoxyharmalan
6-Methoxyharmalan, or 6-methoxyharmalane, also known as 6-methoxy-1-methyl-3,4-dihydro-β-carboline, is a naturally occurring serotonin receptor modulator, monoamine oxidase inhibitor, and hallucinogen of the β-carboline family related to harmaline. It is a cyclized tryptamine and analogue of 5-MeO-DMT and melatonin. The compound has been isolated from Virola species.
Use and effects
6-Methoxyharmalan has been reported to be hallucinogenic in humans at a dose of 1.5mg/kg orally, with slightly greater potency than harmaline. Its onset of action via oral administration is about 1hour. The drug also produces hallucinogenic effects at a dose of 1mg/kg intravenously and with a near-immediate onset by this route. Its hallucinogenic effects are described as similar to those of harmaline. The hallucinogenic effects of β-carbolines like harmaline and 6-methoxyharmalan have been described as qualitatively distinct from those of serotonergic psychedelics like mescaline. On the other hand, they have been said to be similar to those of ibogaine.Pharmacology
Pharmacodynamics
6-Methoxyharmalan shows modest affinity for the serotonin 5-HT2A receptor and for the serotonin 5-HT2C receptor. Its affinity for the serotonin 5-HT2A receptor is similar to that of harmaline. Despite their appreciable affinities for the serotonin 5-HT2A receptor, neither 6-methoxyharmalan nor harmaline showed any agonist or antagonist activity at the receptor at a concentration of 10,000nM. On the other hand, 6-methoxyharmalan has been reported to be a potent serotonin antagonist in other in-vitro systems, such as the isolated rat uterus and isolated guinea pig ileum. 6-Methoxyharmalan does not bind to the serotonin 5-HT1A receptor or the dopamine D2 receptor. However, it does also bind to the serotonin 5-HT6 and 5-HT7 receptors, but not to various other serotonin receptors, the serotonin transporter, or a variety of other targets. The compound has also been reported to be a very weak glycine receptor antagonist. Besides receptor and transporter interactions, 6-methoxyharmalan has been reported to be a potent monoamine oxidase inhibitor.Similarly to harmaline, but in contrast to harman and harmine, 6-methoxyharmalan substitutes for the serotonergic psychedelic DOM in rodent drug discrimination tests. In addition, 6-methoxyharmalan fully substitutes for the atypical hallucinogen ibogaine in drug discrimination tests, whereas harmaline partially to fully substitutes for ibogaine in these tests.
It is unclear whether the serotonin 5-HT2A receptor mediates the hallucinogenic effects of 6-methoxyharmalan and other β-carbolines or not. While 6-methoxyharmalan and harmaline showed no serotonin 5-HT2A receptor agonistic activity in vitro, there could be limitations of the assay or they might have active metabolites that activate the receptor instead, among other possibilities. Alternatively, the hallucinogenic effects of these compounds may not be mediated by serotonin 5-HT2A receptor activation. This would be in accordance with their hallucinogenic effects being described as distinct from those of psychedelics like mescaline but similar to those of the structurally related ibogaine. Moreover, the relatively selective serotonin 5-HT2A receptor antagonist pirenperone did not affect harmaline's substitution of ibogaine in rodent drug discrimination tests.